Health ❯ Healthcare ❯ Oncology

Prostate Cancer

Diagnosis Treatment Localized Prostate Cancer Clinical Trials Metastatic Castration Sensitive Prostate Cancer Androgen Ablation Therapy Treatment Options Symptoms Hormonal Therapy Diagnosis Methods Metastatic Disease MRI Utilization Biomarkers Patient Care BRCA Mutations FDA Approved Drugs Treatment Side Effects PTEN-deficient Tumors Salvage Radiotherapy Metastatic Hormone-Sensitive Prostate Cancer Metastatic Castration-Resistant Prostate Cancer Research Research Studies Psychological Impact Enzalutamide CDK12/13 Inactivation Survival Rates Surgical Treatment Advanced Prostate Cancer Risk Factors Technological Advances Hormone-Sensitive Prostate Cancer Screening Methods HRR Mutations Diagnosis and Treatment VIR-5500 Detection Methods

Erleada Plus Hormone Therapy Cuts Recurrence and Death in High‑Risk Localized Prostate Cancer

Late‑stage trial results signal possible expansion of the Johnson & Johnson drug into earlier‑stage care and now move to regulatory review.

FDA Panel Rejects AstraZeneca Breast Cancer Drug, Backs Prostate Therapy

Pfizer’s Talzenna Plus Xtandi Delivers Phase 3 Win in Hormone-Sensitive Prostate Cancer

Astellas–Vir Prostate Cancer Alliance Launches With New Data as VIR Stock Surges

Study Links PSMA PET/CT to 5-Year Outcomes, Informing Salvage Treatment After Prostatectomy

Final EMBARK Results Show 40% Lower Mortality With Enzalutamide Plus Leuprolide in High-Risk Recurrent Prostate Cancer

CDK12/13 Degraders Activate STING-Mediated Immunity and Enhance Checkpoint Therapy